WO2010148572A1 - Method for treating or ameliorating mucocutaneous or ocular toxicities - Google Patents
Method for treating or ameliorating mucocutaneous or ocular toxicities Download PDFInfo
- Publication number
- WO2010148572A1 WO2010148572A1 PCT/CN2009/072474 CN2009072474W WO2010148572A1 WO 2010148572 A1 WO2010148572 A1 WO 2010148572A1 CN 2009072474 W CN2009072474 W CN 2009072474W WO 2010148572 A1 WO2010148572 A1 WO 2010148572A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- inhibitor
- kinase
- egfr
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2763299A CA2763299C (en) | 2009-06-26 | 2009-06-26 | Method for treating or ameliorating mucocutaneous or ocular toxicities |
EP09846372.2A EP2445533B1 (en) | 2009-06-26 | 2009-06-26 | Method for treating or ameliorating mucocutaneous or ocular toxicities |
CN2009801598486A CN102458473A (en) | 2009-06-26 | 2009-06-26 | Method for treating or ameliorating mucocutaneous or ocular toxicities |
KR1020117029613A KR20130065561A (en) | 2009-06-26 | 2009-06-26 | Method for treating or ameliorating mucocutaneous or ocular toxicities |
KR1020147007209A KR101563362B1 (en) | 2009-06-26 | 2009-06-26 | Pharmaceutical composition for treating or ameliorating toxicities or side effects induced by molecular targeted therapy |
AU2009348848A AU2009348848B2 (en) | 2009-06-26 | 2009-06-26 | Method for treating or ameliorating mucocutaneous or ocular toxicities |
ES09846372.2T ES2621849T3 (en) | 2009-06-26 | 2009-06-26 | Method of treatment or improvement of mucocutaneous or ocular toxicities. |
US13/375,148 US20120114745A1 (en) | 2009-06-26 | 2009-06-26 | Method for treating or ameliorating mucocutaneous or ocular toxicities |
JP2012515308A JP5659395B2 (en) | 2009-06-26 | 2009-06-26 | Method for treating or improving mucocutaneous or ocular toxicity |
PCT/CN2009/072474 WO2010148572A1 (en) | 2009-06-26 | 2009-06-26 | Method for treating or ameliorating mucocutaneous or ocular toxicities |
US14/817,543 US20150335597A1 (en) | 2009-06-26 | 2015-08-04 | Method for treating or ameliorating mucocutaneous or ocular toxicities |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2009/072474 WO2010148572A1 (en) | 2009-06-26 | 2009-06-26 | Method for treating or ameliorating mucocutaneous or ocular toxicities |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/375,148 A-371-Of-International US20120114745A1 (en) | 2009-06-26 | 2009-06-26 | Method for treating or ameliorating mucocutaneous or ocular toxicities |
US14/817,543 Continuation US20150335597A1 (en) | 2009-06-26 | 2015-08-04 | Method for treating or ameliorating mucocutaneous or ocular toxicities |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010148572A1 true WO2010148572A1 (en) | 2010-12-29 |
Family
ID=43385882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/072474 WO2010148572A1 (en) | 2009-06-26 | 2009-06-26 | Method for treating or ameliorating mucocutaneous or ocular toxicities |
Country Status (9)
Country | Link |
---|---|
US (2) | US20120114745A1 (en) |
EP (1) | EP2445533B1 (en) |
JP (1) | JP5659395B2 (en) |
KR (2) | KR101563362B1 (en) |
CN (1) | CN102458473A (en) |
AU (1) | AU2009348848B2 (en) |
CA (1) | CA2763299C (en) |
ES (1) | ES2621849T3 (en) |
WO (1) | WO2010148572A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10583111B2 (en) | 2017-12-13 | 2020-03-10 | Onquality Pharmaceuticals China Ltd. | Method for preventing or treating diseases associated with the inhibition of EGFR |
US10987336B2 (en) | 2018-04-16 | 2021-04-27 | Onquality Pharmaceuticals China Ltd. | Method of preventing or treating side effect of tumor therapy |
US11633486B2 (en) | 2017-04-17 | 2023-04-25 | The University Of Chicago | Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101220261B1 (en) * | 2011-07-27 | 2013-02-07 | 서울대학교산학협력단 | Thermal responsive draw agent for forward osmosis desalination and the forward osmosis desalination method using the draw agent |
KR102255197B1 (en) * | 2014-05-02 | 2021-05-25 | 삼성디스플레이 주식회사 | Organic light emitting device |
CN110755376A (en) * | 2019-12-05 | 2020-02-07 | 河南省人民医院 | Vorinostat water-soluble eye drops and preparation method thereof |
WO2023212841A1 (en) * | 2022-05-05 | 2023-11-09 | Wenzhou Medical University | A kind of polypeptide analog with hair growth effect |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997011366A1 (en) | 1995-09-20 | 1997-03-27 | Merck & Co., Inc. | Histone deacetylase as target for antiprotozoal agents |
WO1998048825A1 (en) | 1997-05-01 | 1998-11-05 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
WO2000008048A2 (en) | 1998-08-04 | 2000-02-17 | Fujisawa Pharmaceutical Co., Ltd. | Inhibitor of histone deacetylase |
CN1414971A (en) * | 1999-12-08 | 2003-04-30 | 埃克斯西特治疗公司 | Depsipeptide and congeners thereof for use as immunosuppressants |
CN1933802A (en) * | 2004-03-26 | 2007-03-21 | 帝斯曼知识产权资产管理有限公司 | Composition comprising an hdac inhibitor in combination with a retinoid |
CN101152179A (en) * | 2006-09-28 | 2008-04-02 | 中国医学科学院药物研究所 | Application of isoniazide as histone deacetylase inhibitors |
CN101175492A (en) * | 2005-03-11 | 2008-05-07 | 科罗拉多大学董事会 | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
CN101222938A (en) * | 2005-07-15 | 2008-07-16 | 拓朴塔格特德国股份公司 | Use of inhibitors of histone deacetylases in combination with NASAID for the therapy of cancer and/or inflammatory diseases |
CN101280317A (en) * | 2008-03-28 | 2008-10-08 | 四川大学 | FAK and EGFR targeted RNA interference plasmid-lipidosome antineoplastic complex |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1574213A (en) * | 1923-04-03 | 1926-02-23 | Ralph G Tyler | Golf club |
US8846039B2 (en) * | 2002-04-26 | 2014-09-30 | Asan Laboratories Company (Cayman), Limited | Method for ameliorating pruritus |
US20060275370A1 (en) * | 2002-07-25 | 2006-12-07 | Yih-Lin Chung | Method and compositions for treatment of epithelial damage |
WO2005023179A2 (en) * | 2003-08-29 | 2005-03-17 | Aton Pharma, Inc. | Combination methods of treating cancer |
DE602004014895D1 (en) * | 2004-03-11 | 2008-08-21 | Asan Lab Company Cayman Ltd | Use of histone deacetylase inhibitors to increase the therapeutic effect in radiotherapy and chemotherapy |
EP2500063A1 (en) * | 2005-02-03 | 2012-09-19 | TopoTarget UK Limited | Combination therapy using HDAC inhibitors and melphalan for treating cancer |
US20080182865A1 (en) | 2005-03-11 | 2008-07-31 | Witta Samir E | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
EP2494965A3 (en) * | 2005-04-15 | 2013-01-02 | The Albert Einstein College Of Medicine Of Yeshiva University | Vitamin K for Prevention and Treatment of Skin Rash Secondary to Anti-EGFR Therapy |
DE102005030553A1 (en) | 2005-06-22 | 2006-12-28 | Aesculap Ag & Co. Kg | Surgical screw box has retainer and fastener component whereby fastener component can be movably mounted on retainer component in closing condition so that only single screw retainer is accessible for insert and withdrawal of bone screw |
AU2006287378A1 (en) * | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by HDac inhibition |
CA2660782A1 (en) * | 2006-06-26 | 2008-01-03 | Novartis Ag | Organic compounds |
CN101380317B (en) * | 2007-09-07 | 2010-12-08 | 英属开曼群岛商安盛开发药物股份有限公司 | Pharmaceutical composition for easing pruritus |
US20090149511A1 (en) | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
-
2009
- 2009-06-26 CN CN2009801598486A patent/CN102458473A/en active Pending
- 2009-06-26 US US13/375,148 patent/US20120114745A1/en not_active Abandoned
- 2009-06-26 WO PCT/CN2009/072474 patent/WO2010148572A1/en active Application Filing
- 2009-06-26 KR KR1020147007209A patent/KR101563362B1/en active IP Right Grant
- 2009-06-26 ES ES09846372.2T patent/ES2621849T3/en active Active
- 2009-06-26 EP EP09846372.2A patent/EP2445533B1/en not_active Not-in-force
- 2009-06-26 CA CA2763299A patent/CA2763299C/en not_active Expired - Fee Related
- 2009-06-26 AU AU2009348848A patent/AU2009348848B2/en not_active Ceased
- 2009-06-26 JP JP2012515308A patent/JP5659395B2/en not_active Expired - Fee Related
- 2009-06-26 KR KR1020117029613A patent/KR20130065561A/en active Application Filing
-
2015
- 2015-08-04 US US14/817,543 patent/US20150335597A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997011366A1 (en) | 1995-09-20 | 1997-03-27 | Merck & Co., Inc. | Histone deacetylase as target for antiprotozoal agents |
WO1998048825A1 (en) | 1997-05-01 | 1998-11-05 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
WO2000008048A2 (en) | 1998-08-04 | 2000-02-17 | Fujisawa Pharmaceutical Co., Ltd. | Inhibitor of histone deacetylase |
CN1414971A (en) * | 1999-12-08 | 2003-04-30 | 埃克斯西特治疗公司 | Depsipeptide and congeners thereof for use as immunosuppressants |
CN1933802A (en) * | 2004-03-26 | 2007-03-21 | 帝斯曼知识产权资产管理有限公司 | Composition comprising an hdac inhibitor in combination with a retinoid |
CN101175492A (en) * | 2005-03-11 | 2008-05-07 | 科罗拉多大学董事会 | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
CN101222938A (en) * | 2005-07-15 | 2008-07-16 | 拓朴塔格特德国股份公司 | Use of inhibitors of histone deacetylases in combination with NASAID for the therapy of cancer and/or inflammatory diseases |
CN101152179A (en) * | 2006-09-28 | 2008-04-02 | 中国医学科学院药物研究所 | Application of isoniazide as histone deacetylase inhibitors |
CN101280317A (en) * | 2008-03-28 | 2008-10-08 | 四川大学 | FAK and EGFR targeted RNA interference plasmid-lipidosome antineoplastic complex |
Non-Patent Citations (49)
Title |
---|
ANDREWS ET AL., INTERNATIONAL J. PARASITOLOGY, vol. 30, 2000, pages 761 - 768 |
BIADE ET AL., INT. J. RADIAT. BIOL, vol. 77, 2001, pages 1033 - 1042 |
BOSCH ET AL., PLANT CELL, vol. 7, 1995, pages 1941 - 1950 |
CHEN ET AL., SCIENCE, vol. 293, 2001, pages 1653 - 1657 |
COUSENS ET AL., J. BIOL. CHEM., vol. 254, 1979, pages 1716 - 1723 |
DARKIN-RATTRAY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 13143 - 13147 |
FERRANDINA ET AL., ONCOL. RES., vol. 12, 2001, pages 429 - 440 |
GALIMONT-COLLEN AFS ET AL., EUR J CANCER, vol. 43, 2007, pages 845 - 851 |
GARBER ET AL., J. NATL. CANCER INST., vol. 94, 2002, pages 793 - 795 |
GOTTLICHER ET AL., EMBO J., vol. 20, 2001, pages 6969 - 6978 |
GUAN ET AL., CANCER RESEARCH, vol. 60, 2000, pages 749 - 755 |
HUANG ET AL., CYTOKINE, vol. 9, 1997, pages 27 - 36 |
JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO. |
KIJIMA ET AL., J. BIOL. CHEM., vol. 268, 1993, pages 22429 - 22435 |
KIM ET AL., ONCOGENE, vol. 18, 1999, pages 2461 - 2470 |
KOGHE ET AL., BIOCHEM. PHARMACOL, vol. 56, 1998, pages 1359 - 1364 |
KRAMER ET AL., TRENDS ENDOCRINOL. METAB., vol. 12, 2001, pages 294 - 300 |
KWON ET AL., PNAS, vol. 95, 1998, pages 3356 - 3361 |
LACOUTURE ME, NAT REV CANCER, vol. 6, 2006, pages 803 - 812 |
LAGGER ET AL., EMBO J., vol. 21, 2002, pages 2672 - 2681 |
LEA; TULSYAN, ANTICANCER RESEARCH, vol. 15, 1995, pages 879 - 873 |
LEONI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, 2002, pages 2995 - 3000 |
LIBERMAN, H. A. AND LACHMAN, L.,: "Pharmaceutical Dosage Forms", 1980, MARCEL DECKER |
MARKS ET AL., J. NATL. CANCER INST., vol. 92, 2000, pages 1210 - 1216 |
MASCIA F ET AL., AM J PATHOL, vol. 163, 2003, pages 303 - 312 |
MCBAIN ET AL., BIOCHEM. PHARM, vol. 53, 1997, pages 1357 - 1368 |
MIETTINEN PJ ET AL., NATURE, vol. 376, 1995, pages 337 - 341 |
MILLER ET AL., INT. J. RADIAT. BIOL, vol. 72, 1997, pages 211 - 218 |
MISHRA ET AL., PROC. NATL. ACAD. SCI. USA., vol. 98, 2001, pages 2628 - 2633 |
NAKAJIMA ET AL., EX. CELL RES, vol. 241, 1998, pages 126 - 133 |
PASTORE S ET AL., J LMMUNO, vol. 174, 2005, pages 5047 - 5056 |
PEREZ-SOLER R ET AL., J CLIN ONCOL, vol. 23, 2005, pages 5235 - 5246 |
QIU ET AL., MOL. BIOL. CELL, vol. 11, 2000, pages 2069 - 2083 |
RICHON ET AL., CLIN. CANCER RES., vol. 8, 2002, pages 662 - 667 |
RICHON ET AL., PNAS, vol. 95, 1998, pages 3003 - 3007 |
RICHON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 3003 - 3007 |
RICHON ET AL., PROC. NATL. ACAD. SCI. USA., vol. 97, 2000, pages 10014 - 10019 |
ROMBOUTS ET AL., ACTA GASTROENTEROL. BELG., vol. 64, 2001, pages 239 - 246 |
SAITO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 4592 - 4597 |
SAUNDERS ET AL., CANCER RES., vol. 59, 1999, pages 399 - 404 |
See also references of EP2445533A4 |
SEGAIN ET AL., GUT, vol. 47, 2000, pages 397 - 403 |
STOCKHAMMER ET AL., J. NEUROSURG., vol. 83, 1995, pages 672 - 681 |
SU ET AL., CANCER RESEARCH, vol. 60, 2000, pages 3137 - 3142 |
VAN LINT ET AL., GENE EXPR., vol. 5, 1996, pages 245 - 243 |
VIGUSHIN ET AL., CLIN. CANCER RES., vol. 7, 2001, pages 971 - 976 |
WANG ET AL., CANCER RESEARCH, vol. 59, 1999, pages 2766 - 2799 |
WARRELL ET AL., J. NATL. CANCER INST., vol. 90, 1998, pages 1621 - 1625 |
WEBB ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 14280 - 14287 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11633486B2 (en) | 2017-04-17 | 2023-04-25 | The University Of Chicago | Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease |
US10583111B2 (en) | 2017-12-13 | 2020-03-10 | Onquality Pharmaceuticals China Ltd. | Method for preventing or treating diseases associated with the inhibition of EGFR |
US10987336B2 (en) | 2018-04-16 | 2021-04-27 | Onquality Pharmaceuticals China Ltd. | Method of preventing or treating side effect of tumor therapy |
EP3782618A4 (en) * | 2018-04-16 | 2022-01-26 | OnQuality Pharmaceuticals China Ltd. | Method for preventing or treating side effects of cancer therapy |
Also Published As
Publication number | Publication date |
---|---|
US20120114745A1 (en) | 2012-05-10 |
JP2012530076A (en) | 2012-11-29 |
KR20140041956A (en) | 2014-04-04 |
CA2763299C (en) | 2015-11-24 |
AU2009348848B2 (en) | 2012-10-25 |
EP2445533B1 (en) | 2017-02-08 |
EP2445533A1 (en) | 2012-05-02 |
AU2009348848A1 (en) | 2011-12-01 |
JP5659395B2 (en) | 2015-01-28 |
KR20130065561A (en) | 2013-06-19 |
US20150335597A1 (en) | 2015-11-26 |
CA2763299A1 (en) | 2010-12-29 |
EP2445533A4 (en) | 2014-07-23 |
KR101563362B1 (en) | 2015-10-26 |
ES2621849T3 (en) | 2017-07-05 |
CN102458473A (en) | 2012-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20150335597A1 (en) | Method for treating or ameliorating mucocutaneous or ocular toxicities | |
CN100574804C (en) | The medical composition of treatment gastrointestinal upset | |
US9370524B2 (en) | Method for reducing radiation-induced normal tissue damage | |
EP2033635B1 (en) | Use of phenylbutyric acid or salts thereof for treating pruritus | |
WO2007070694A2 (en) | Spray-on formulations and methods for dermal delivery of drugs | |
KR20190141661A (en) | Methods for treating and / or preventing actinic keratosis | |
KR20170018852A (en) | Topical compositions and methods for treating wounds | |
US8492438B2 (en) | Treatment skin disorders | |
EP1574213A1 (en) | Use of histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy | |
EP1719543A1 (en) | Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress | |
US8946295B2 (en) | Histone hyperacetylating agents for promoting wound healing and preventing scar formation | |
US8163764B2 (en) | Skincare methods | |
JP4974813B2 (en) | Ways to relieve itch | |
TWI412359B (en) | Use of histone deacetylase inhibitor in manufacturing a medicament for treating or ameliorating mucocutaneous or ocular toxicities or side effects | |
AU2011213694B2 (en) | Treatment skin disorders | |
AU2009202036A1 (en) | Method for Ameliorating Pruritus | |
CA2601999C (en) | Method for ameliorating pruritus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980159848.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09846372 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009348848 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2763299 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13375148 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2009348848 Country of ref document: AU Date of ref document: 20090626 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20117029613 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2009846372 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009846372 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012515308 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |